White matter hyperintensities (WMHs) are frequently characterized as markers of cerebrovascular disease, whereas medial temporal atrophy (MTA) is a recognized marker of Alzheimer disease (AD). Our purpose was to test the reliability of a visual rating system (VRS) in evaluating WMHs and MTA and in distinguishing healthy from cognitively impaired subjects.
T
he presence of white matter hyperintensities (WMHs), observed as bright foci on T2-weighted MR images, 1 occurs commonly among elderly cognitively healthy subjects and in those with mild cognitive impairment (MCI) and a variety of dementias, including Alzheimer disease (AD). [2] [3] [4] [5] [6] The etiology of these WMHs has most frequently been ascribed to normal aging and cerebrovascular disease, even among subjects with dementia diagnosed with probable Alzheimer disease. 6, 7 There is growing evidence, however, that neurodegeneration or associated processes, such as gliosis, microglial infiltration, inflammation, and amyloid angiopathy, may also result in WMHs. [8] [9] [10] [11] [12] [13] The pathologic process characteristic of AD begins in the medial temporal structures, and the attenuation of this pathology has a proportional effect on the degree of atrophy in these structures (especially the hippocampus and entorhinal cortex).
14 Medial temporal atrophy (MTA) can be identified accurately from MR images and correlates with the severity of AD-related neuropathologic changes at autopsy. 15 The severity of MTA can serve as a substitute for the severity of AD and other degenerative pathology in the medial temporal lobe. [16] [17] [18] We have developed a computer-assisted visual rating system (VRS) that uses drop-down reference images to illustrate the anatomy and demonstrate different levels of atrophy of medial temporal structures. 19, 20 This system has high interrater and intrarater reliability and distinguishes subjects with no cognitive impairment from those with amnestic MCI (a-MCI) and probable AD purely on the basis of measurements of MTA. 19, 20 We have now adjusted the VRS so that procedures analogous to those used for MTA measurements can be used to rate WMHs in the periventricular and centrum semiovale regions of the brain.
In this study, we tested inter-and intrarater reliability of the VRS in evaluating WMHs in the periventricular and centrum semiovale regions. We also examined the ability of VRS-WMH ratings to distinguish subjects diagnosed with no cognitive impairment, nonamnestic mild cognitive impairment (na-MCI), a-MCI, and probable AD, among 192 subjects enrolled in the Florida Alzheimer's Disease Research Center. Recent studies have linked cerebrovascular risk factors such as diabetes, 21 coronary heart disease, 22 31 The a-MCI diagnosis was made according to the criteria of Petersen et al. 32 The diagnosis of no cognitive impairment required that informants report "no significant decline in cognition" and that no cognitive test scores were more than 1.5 SD below age-and education-corrected means. The na-MCI diagnosis required that no memory test score be more than 1.5 SD below education-corrected normative values but that 1 or more nonmemory test score be greater than 1.5 SD below normative values.
MR Imaging Procedures
Siemens Symphony 1.5T. Brain MR imaging scans were obtained on a Symphony 1.5T scanner (Siemens, Erlangen, Germany) by using a proprietary 3D magnetization-prepared rapid acquisition of gradient echo (3D MPRAGE) protocol. Images were obtained from the vertex of the skull to the foramen magnum and from the occipital poles to the temporal poles. Specifications for 3D MPRAGE were the following: 120 contiguous coronal sections with a 1.5-mm gap in thickness; section interval, 0.75 mm; TR, 2190 ms; TE, 4.38 ms; TI, 1100 ms; FA, 15°; NEX, 1; matrix, 256 ϫ 256; FOV, 260 mm; bandwidth, 130 Hz/pixel; acquisition time, 9 minutes; phase-encoding direction, right to left. MTA was evaluated by atrophy rating of the hippocampus, entorhinal cortex, and the perirhinal cortex on a coronal section intersecting the mamillary bodies.
For WMH assessment, images were obtained by using a fluidattenuated inversion recovery (FLAIR) turbo spin-echo protocol. Images were obtained from the vertex of the skull to the foramen magnum. Specifications for FLAIR sequences were the following: 20 contiguous axial sections of 5.5-mm thickness; section interval, 1.9 mm; TR, 9000 ms; TE, 109 ms; TI, 2500 ms; flip of preparation pulse, 150°; echo-train length, 19 VRS in Assessing MTA. We developed the VRS to promote standardization, increase reliability, and prevent reliability drift among raters for a semiquantitative visual rating of various radiologic features of interest on brain MR images. 19 VRS uses a 0 -4 scale to rate atrophy of the medial temporal lobe structures, including the hippocampus, entorhinal cortex, and perirhinal cortex as follows: 0 ϭ no atrophy, 1 ϭ minimal atrophy, 2 ϭ mild atrophy, 3 ϭ moderate atrophy, 4 ϭ severe atrophy. The VRS program includes drop-down menus linked to reference images that visualize the anatomy of the brain structures and provide examples of different levels of atrophy or abnormality of radiologic features based on a scale of 0 -4. After the rater determines ratings by comparing MR images to VRS reference images, the program provides a data base in which VRS ratings are catalogued and stored. VRS also provides a training module that contains a series of normal and abnormal findings on scans, which can be rated and compared with the reference ratings. This feature provides feedback to the rater and improves the accuracy and reliability of VRS data. 19 We have previously reported that MTA ratings distinguish subjects with probable AD from those with a-MCI and those with a-MCI from those with no cognitive impairment.
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VRS Assessment of WMHs
VRS was used to evaluate WMHs on FLAIR sequences in 4 periventricular WMH regions (frontal, parietal, occipital, and temporal), and the centrum semiovale WMH region, by using a 0 -4 severity scale (Figs 1 and 2). Criteria for periventricular WMH ratings were based on extension of WMHs from the lateral ventricle to the cerebral cortex as follows: 0 ϭ no detectable WMH, 1 ϭ thin rim (pencil edge) of hyperintensity adjacent to the ventricle, 2 ϭ extension of WMHs to one third of the distance to the cerebral cortex, 3 ϭ extension of WMHs to two thirds of the distance to the cerebral cortex, 4 ϭ extension of WMHs to the cerebral cortex. Criteria for centrum semiovale WMHs were based on the anteroposterior extent of WMHs in the centrum semiovale as follows: 0 ϭ no centrum semiovale WMHs, 1 ϭ at least 1 centrum semiovale WMH Յ1 cm in greatest dimension, 2 ϭ at least 1 centrum semiovale WMH Ͼ1 cm in dimension, 3 ϭ multiple coalescing centrum semiovale WMHs occupying less than two thirds of the anteroposterior extent of WMHs in the centrum semiovale, 4 ϭ multiple coalescing centrum semiovale WMHs occupying more than two thirds of the anteroposterior extent of WMHs in the centrum semiovale. Justification for the use of severity ratings to judge WMHs, rather than using terminology such as "punctuate" or "confluent," is that this a simple and direct measure of the extent of abnormal hyperintensity and, therefore, very likely pathologic white matter on the brain MR imaging. There is no evidence that terms such as "punctuate" or "confluent" have specific biologic significance or are superior to severity measures. In fact, automated procedures have been developed to measure the area or volume of white matter that reaches a specific threshold of hyperintensity on MR imaging. These measures, which are more quantitative than our measures but are essentially severity measures, have been shown to be related to cognitive status.
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Cardiovascular Risk Factor Assessment
The cardiovascular risk factor score was calculated as a sum of 10 independent risk factors selected from the NACC/Uniform Data Set assessment protocol (Form A5: "Subject Health History"; www.alz. washington.edu/MOVIES/UDSdemoforms.pdf). These factors were rated as "present" or "absent" and included the following: 1) "Heart attack/cardiac arrest," 2) "Atrial fibrillation," 3) "Angioplasty/endarterectomy/coronary artery bypass surgery," 4) "Congestive Heart failure," 5) "Stroke/TIA" (transient ischemic attack), 6) "Hypertension," 7) "Hypercholesterolemia," 8) "Diabetes," 9) "Smoked within last 30 days," and 10) "Smoked more than 100 cigarettes in his/her life."
Statistical Methods
Statistical Analyses. To test interrater reliability of the VRS in evaluating WMHs, 2 raters evaluated axial FLAIR brain MR images of 30 subjects diagnosed with no cognitive impairment (n ϭ 10), MCI (n ϭ 10), or AD (n ϭ 10). WMHs were assessed in the periventricular frontal, parietal, occipital, and temporal regions and in the centrum semiovale region. VRS raters were blinded to the identity and diagnosis of the subjects. To test intrarater reliability of the VRS, a single rater re-evaluated axial FLAIR brain MR images in 21 of the original 30 subjects after an interval of approximately 3 weeks. Group comparisons of atrophy and WMH scores were analyzed by using a series of 1-way analyses of variance (ANOVA). The Scheffe post hoc procedure was used to examine differences between means. Logistic regression was used to determine the correct classification of specific subject groups on the basis of WMH scores.
Results
Weighted exhibited a high degree of correspondence with respect to interrater and intrarater reliability for bilateral frontal, parietal, occipital, and centrum semiovale brain regions and a moderate degree of correspondence for temporal regions (Table 1) . For all brain regions, intrarater reliabilities were achieved in the good-to-excellent range. There were group differences ( Scheffe post hoc procedure tests indicated that subjects with no cognitive impairment were younger than patients with a-MCI and dementia. Subjects classified as having no cognitive impairment were also more highly educated than subjects in the na-MCI group. Subjects with no cognitive impairment had the highest mean MMSE scores, followed by a-MCI and na-MCI groups. The lowest average MMSE scores were obtained by the probable AD group. There were no group differences with regard to sex distribution [X 2 (df ϭ 3) ϭ 4.89; P Ͼ .18]. Although there were differences in age between the groups, we chose not to covary by age in the ANOVA models. Because age is a risk factor for both AD and a-MCI, whereas AD and MCI are associated with increased MTA, covarying for age can obscure a true effect of the disease state on outcome measures. Miller and Chapman 35 concluded that ANOVA was not designed to correct for systematic differences in natural unrandomized groups and can lead to spurious findings. Subjects with probable AD had higher average WMH scores in all brain regions relative to subjects with no cognitive impairment (Table 3 ). In addition, subjects with probable AD had higher WMH scores in all regions, relative to subjects with na-MCI, except in the right frontal and right occipital lobes. Although subjects with probable AD had higher mean WMH scores than subjects with a-MCI in the left centrum semiovale, they did not differ with respect to WMH scores in other brain regions.
Average MTA scores differentiated subjects with no cognitive impairment and those with na-MCI from those with a-MCI (Table 4) . Furthermore, those subjects with probable AD had higher average MTA scores in comparison with subjects in other diagnostic groups. Subjects with probable AD were differentiated from those with na-MCI and MCI on the basis of total WMH scores but did not differ from subjects with a-MCI. Average cardiovascular risk factor scores did not differ across the diagnostic groups. MTA ratings generated by the VRS did correlate with total WMH (r ϭ 0.39; P Ͻ .001) ratings because WMHs in all regions were significantly associated with MTA scores (Table 5 ). There were no significant associations between total WMH scores and total cardiovascular risk factor scores (r ϭ 0.07, P ϭ ns). Although a weak association was noted between cardiovascular risk factor scores and periventricular WMH ratings in the left occipital region (r ϭ 0.15; P Ͻ .05), it is very likely that this represented a spurious finding associated with multiple comparisons.
With logistic regression, correct classification rates for no cognitive impairment versus a-MCI were 62% for centrum semiovale WMHs, 60% for periventricular WMHs, and 62% for total WMHs, respectively. When classification accuracy of no cognitive impairment versus AD subjects was computed, ratings for centrum semiovale WMH, periventricular WMH, and total WMH yielded correct classification of 70%, 70%, and 69% of subjects, respectively.
Stepwise logistic regression was used to determine the extent that cardiovascular risk factors, MTA, centrum semiovale WMHs, and age discriminated between subjects with probable AD versus no cognitive impairment and those with a-MCI versus no cognitive impairment. Results indicated that the overall MTA score distinguished subjects with probable AD from those with no cognitive impairment with a 75.9% sensitivity and 86.5% specificity, with an overall correct Note:-MTA indicates medial temporal atrophy; CVRF, cardiovascular risk factor. * Means with different alphabetic superscripts (a,b,c) are significantly different at P Ͻ .05 by the Scheffe post hoc procedure. † P Յ .01. ‡ P Ͻ .001. 
Discussion
In clinical neurologic and radiologic practice, "WMHs on MR images" and "ischemic microvascular lesions" are frequently considered to be overlapping terms. 8, 9, 34 As a consequence, many clinicians diagnose vascular dementia 8 or exclude a diagnosis of AD on the basis of evidence of widespread WMHs on MR images. However, among elderly individuals with cognitive impairment and dementia, neuropathologic studies provide a much different etiologic perspective for WMHs, demonstrating the heterogeneity of these lesions. [10] [11] [12] [13] Among patients with AD, the most representative neuropathologic correlates of WMHs on MR imaging are microglial activation, gliosis, rarefaction of white matter, wallerian degeneration, nonamyloid sclerosis, and reduced attenuation of blood vessels. [10] [11] [12] [13] The results of the current study also suggest that degenerative disease or conditions associated with degenerative disease are the principal etiologic factors related to WMHs, rather than vascular disease.
In our study, both periventricular WMHs and centrum semiovale WMHs were consistently associated with MTA scores, which, in turn, were strongly correlated with the severity of cognitive impairment. MTA scores are a substitute for the severity of pathology in medial temporal regions [14] [15] [16] [17] and can be used to assist in the diagnosis of AD, even in a predementia stage. 20 MR imagingϪbased measurements of hippocampal volume loss are highly correlated with the rate of progression of MCI to AD. 36, 37 In our study, WMH and MTA scores did not distinguish subjects with no cognitive impairment and those with na-MCI but did distinguish subjects with probable AD, who had higher WMH and MTA scores, from those with no cognitive impairment and those with na-MCI. Similarly, subjects with a-MCI had higher centrum semiovale WMHs and MTA scores than those with no cognitive impairment, but subjects with probable AD and a-MCI were indistinguishable by MTA and WMH scores.
Although the severity of WMHs was independently related to MTA scores, WMH scores had no correlation to cardiovascular risk factor scores, other than very weak correlations to single periventricular WMH and centrum semiovale WMH regions. Studies that have examined the relationship of WMHs on brain MR imaging to MR imaging diffusion characteristics among patients diagnosed with AD show that an increase in the apparent diffusion coefficient in water appears to be the underlying cause of the signal-intensity hyperintensity in these subjects. 38 The underlying neuropathologic correlate that is specific to WMHs among patients with a pathologic diagnosis of AD is microglial activation. Changes in myelin and axonal attenuation seen in areas involved with WMHs may be related to this inflammatory process. 10 The association of WMHs to cardiovascular risk factors in unselected generally cognitively healthy elderly individuals without dementia is well known. However, among individuals with dementia, the vast majority of whom have underlying AD and WMHs, it would seem that there is very little evidence to support a vascular etiology as a cause for the greater severity of WMHs on MR imaging in these individuals. The notion that WMHs are usually related to microvascular disease may not apply to patients with MCI and dementia but may apply to individuals with vascular dementia or with no cognitive impairment at the time of death. 11, 12, 37 Similarly, it would seem that in the absence of any clinical evidence of cerebrovascular disease, clinical logic should argue that in patients who are diagnosed with AD, the presence of WMHs would suggest a white matter pathology caused by the underlying disease that we know is present, rather than by a disease that we speculate might be present. The relatively limited pathologic studies that have been performed to investigate the etiology of WMHs in patients with AD suggest that inflammation with microglial activation may be the underlying etiology of these WMHs, rather than cerebrovascular disease. Similar to the findings of authors from other studies, we did not find a particular location of the WMHs to be specifically associated with degenerative or vascular markers. 39, 40 In this cross-sectional study, we found that the severity of periventricular WMHs, centrum semiovale WMHs, and MTA generally increased with the severity of cognitive impairment, from no cognitive impairment to probable AD. However, we were unable to show any independent relationship of the severity of WMHs to cognitive function in this study. Other cross-sectional studies have also not found an independent association of WMHs to cognitive function. 41, 42 Nevertheless, several longitudinal studies do show that the severity of WMHs at baseline is associated with the rate of progression of cognitive impairment, [43] [44] [45] and at least 1 study has demonstrated that this association is independent of the effects of MTA. 43 However, it is not possible to conclude from these results, as has been done previously, 43 that the faster rate of progression associated with WMHs is related to the synergistic combination of vascular disease, represented by the WMHs, and degenerative disease. In fact, the propensity of subjects who progress faster to have more WMHs may merely indicate that these subjects have more severe and complicated disease, with multiple factors associated with degeneration.
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Conclusions
Elderly patients presenting with MCI and dementia, regardless of whether they are diagnosed with probable or prodromal AD, often have evidence of cerebrovascular disease, in addition to the pathologic features of AD on neuropathologic examination. 46, 47 It is possible that WMHs on MR images of patients with a primary neuropathologic diagnosis of AD represent the presence of vascular lesions, which may not by themselves contribute to the severity of cognitive and functional impairment. However, in our study, we found that WMH scores increased progressively from no cognitive impairment to a-MCI to probable AD. We also found that MTA scores, but not WMH scores, were independently and strongly related to the severity of cognitive impairment. Most interesting, mean WMH scores in na-MCI and no cognitive impairment were not different, even though it would have been expected that if WMHs were associated with vascular pathology, then subjects with na-MCI, who tend to have more vascular disease than those with a-MCI, 31, 32, 35 would have higher WMH scores than those with a-MCI. In fact, we found that the opposite was the case, suggesting that WMHs in subjects who are cognitively impaired are more strongly associated with neurodegenerative disease than with vascular disease. The strengths of the current study are the large number of subjects evaluated and the detailed neuropsychological, clinical, and MR imaging studies of both WMHs and MTA in the same subjects. Furthermore, the inclusion of subjects with both a-MCI and na-MCI provided the opportunity to evaluate WMH and MTA scores in the earliest stages of dementia, presumably caused by both AD (a-MCI) and non-AD (na-MCI) pathology. Limitations of this study include the lack of longitudinal data, which would have added another dimension to interpretation of the results, and lack of clinicopathologic correlations between WMHs and pathologic findings. Nevertheless, the current study does provide important support for the hypothesis that WMHs are most likely related to degenerative rather than vascular pathology among subjects diagnosed with na-MCI, a-MCI, and probable AD.
